The case for & against
Bull & Bear analysis
Bearish
Varex Imaging Corporation (NASDAQ: VREX) is a key player in the medical and industrial imaging sectors, specializing in advanced imaging solutions for both diagnostic and cargo inspection applications. The company is positioned to leverage significant opportunities in areas such as high-energy linear accelerators and X-ray technologies. Varex is not only catering to the healthcare industry's growing demands but also witnessing robust growth in the industrial sector, particularly driven by security inspection systems globally.
Bull says
- ↑Q3 revenue guidance at $215–216.6M implies 6.7% YoY growth.
- ↑Industrial segment sales rose ~17% YoY, driving strong order intake.
- ↑Photon counting R&D and product upgrades support future innovation.
- ↑Strong cash position ($155M) and strategic debt reduction fuel expansion.
- ↑High earnings yield and robust book-to-price suggest undervaluation.
- ↑Positive momentum indicators signal potential share price appreciation.
Bear says
- ↓Weak growth and profitability factors signal operational challenges.
- ↓China tariffs (125%) could erode ~$20M Q3 sales and margins.
- ↓Operating expenses spiked to $148M, including $94M goodwill impairment.
- ↓Gross debt of $370M elevates refinancing risk amid rising rates.
- ↓Top 10 customers represent >52% of sales, raising concentration risk.
- ↓Tariffs clip 100–200bps gross margin, further pressuring profitability.
Investment themes with VREX
Medical Devices↓ -0.50%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 06-04-2026neutral
Transcript signals
Bull points
- We continued to see strong demand in the second quarter, which resulted in revenue near the high end of our expectations.
- Gross margin of 36% in the quarter was higher than anticipated. This was primarily the result of improved volume, favorable product-sales mix, and productivity gains in both segments.
- Cash generation was strong, with cash from operations of $17 million in the quarter. This was driven by improved profitability and continued solid working capital management.
Bear points
- we currently expect that the 125% tariff imposed by China on the US products could negatively impact sales by about $20 million in the third quarter. This is primarily due to a pause in purchases by some of our China-based customers.
- We expect the impact on our gross margins net of the mitigation efforts to be in the 150 to 200 basis point range on a go-forward basis.
- Under the current tariff environment, we see sales impact of roughly $20 million in China and gross margin impact of 150 to 200 basis points driven by increase in cost of goods sold, net of price increases to customers.
Read full transcript analysis ›